TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-κB dependent induction of cFLIPL

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Lluis, Josep Maria ^a   Nachbur, Ulrich ^a   Cook, Wendy Diane ^a   Gentle, Ian Edward ^a   Moujalled, Donia ^a   Moulin, Maryline ^a   Wong, Wendy Wei Lynn ^a   Khan, Nufail ^a   Chau, Diep ^a   Callus, Bernard Andrew ^b   Vince, James Edward ^c   Silke, John ^a   Vaux, David Lawrence ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CASPASE 8; CFLAR PROTEIN, MOUSE; FLICE INHIBITORY PROTEIN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PRIMER DNA; TNFSF10 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL SURVIVAL; CFLIPL GENE; CIAP2 GENE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE; MOUSE; NONHUMAN; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; BASE SEQUENCE; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL SURVIVAL; CELLS, CULTURED; DNA PRIMERS; FIBROBLASTS; MAP KINASE KINASE KINASES; MICE; MICE, KNOCKOUT; NF-KAPPA B; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77649151246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008620     Document Type: Article

References (42)

1. Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607-623.
2. Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14: 359-372.
3. Djerbi M, Darreh-Shori T, Zhivotovsky B, Grandien A (2001) Characterization of the human FLICE-inhibitory protein locus and comparison of the antiapoptotic activity of four different flip isoforms. Scand J Immunol 54: 180-189.
4. Ueffing N, Keil E, Freund C, Kuhne R, Schulze-Osthoff K, et al. (2008) Mutational analyses of c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment. Cell Death Differ 15: 773-782.
5. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, et al. (2001) Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 117: 360-364.
6. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, et al. (2003) Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043.
7. Remmelink M, Mijatovic T, Gustin A, Mathieu A, Rombaut K, et al. (2005) Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. Int J Oncol 26: 247-258.
8. Ryu BK, Lee MG, Chi SG, Kim YW, Park JH (2001) Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 194: 15-19.
9. Clarke P, Tyler KL (2007) Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis 12: 211-223.
10. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, et al. (2008) Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL-and CD95L-mediated apoptosis. Oncogene 27: 3211-3220.
11. Sharp DA, Lawrence DA, Ashkenazi A (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280: 19401-19409.
12. Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H (2002) Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med 8: 725-732.
13. Wang P, Zhang J, Bellail A, Jiang W, Hugh J, et al. (2007) Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 19: 2237-2246.
14. Hu WH, Johnson H, Shu HB (1999) Tumor necrosis factor-related apoptosisinducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274: 30603-30610.
15. Jin Z, El-Deiry WS (2006) Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 26: 8136-8148.
16. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, et al. (2000) The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20: 6638-6645.
17. Harper N, Farrow SN, Kaptein A, Cohen GM, MacFarlane M (2001) Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 276: 34743-34752.
18. Diessenbacher P, Hupe M, Sprick MR, Kerstan A, Geserick P, et al. (2008) NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol 128: 1134-1147.
19. Kim SH, Ricci MS, El-Deiry WS (2008) Mcl-1: a gateway to TRAIL sensitization. Cancer Res 68: 2062-2064.
20. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM (2002) Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 277: 575-585.
21. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, et al. (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280: 40599-40608.
22. Adhikari A, Xu M, Chen ZJ (2007) Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226.
23. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, et al. (1999) The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
24. Morioka S, Omori E, Kajino T, Kajino-Sakamoto R, Matsumoto K, et al. (2009) TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene 28: 2257-2265.
25. Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, Sato S, et al. (2006) Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther 5: 2970-2976.
26. Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, Fumarola C, Farkas T, et al. (2009) TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 28: 677-685.
27. Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, et al. (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118: 100-110.
28. Vince JE, Wong WW, Khan N, Feltham R, Chau D, et al. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131: 682-693.
29. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, et al. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6: 1087-1095.
30. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, et al. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351.
31. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, et al. (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278: 18485-18490.
32. Safwat N, Ninomiya-Tsuji J, Gore AJ, Miller WL (2005) Transforming growth factor beta-activated kinase 1 is a key mediator of ovine follicle-stimulating hormone beta-subunit expression. Endocrinology 146: 4814-4824.
33. Beisner DR, Ch'en IL, Kolla RV, Hoffmann A, Hedrick SM (2005) Cutting edge: innate immunity conferred by B cells is regulated by caspase-8. J Immunol 175: 3469-3473.
34. Chen ZJ, Bhoj V, Seth RB (2006) Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ 13: 687-692.
35. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, et al. (1997) IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278: 860-866.
36. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, et al. (2003) Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278: 20593-20602.
37. Noutomi T, Itoh M, Toyota H, Takada E, Mizuguchi J (2009) Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep 22: 1169-1172.
38. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, et al. (2009) Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAILdependent liver damage. J Exp Med 206: 1727-1737.
39. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, et al. (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24: 8541-8555.
40. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, et al. (2003) Erythroid differentiation sensitizes K562 leukemia cells to TRAILinduced apoptosis by downregulation of c-FLIP. Mol Cell Biol 23: 1278-1291.
41. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, et al. (2007) c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67: 5754-5762.
42. Poukkula M, Kaunisto A, Hietakangas V, Denessiouk K, Katajamaki T, et al. (2005) Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 280: 27345-27355.